{"id":38200,"date":"2024-04-30T11:39:43","date_gmt":"2024-04-30T09:39:43","guid":{"rendered":"https:\/\/www.silvereco.org\/en\/?p=38200"},"modified":"2026-01-22T13:48:50","modified_gmt":"2026-01-22T12:48:50","slug":"neuroclues-raises-5-million-euros-and-prepares-to-launch-its-measurement-solution-to-diagnose-neurological-diseases-such-as-parkinsons-more-quickly","status":"publish","type":"post","link":"https:\/\/www.silvereco.org\/en\/neuroclues-raises-5-million-euros-and-prepares-to-launch-its-measurement-solution-to-diagnose-neurological-diseases-such-as-parkinsons-more-quickly\/","title":{"rendered":"neuroClues\u00ae raises 5 million Euros and prepares to launch its measurement solution to diagnose neurological diseases such as Parkinson’s more quickly."},"content":{"rendered":"\n

neuroClues\u00ae, a Franco-Belgian medTech specialized in diagnosing neurodegenerative diseases, announces a 5 million Euros funding round led by White Fund and the EIC Accelerator program of the European Commission, alongside existing investors Invest.BW, and Business Angels such as Fiona du Monceau, President of the Board of UCB, Artwall, or Olivier Legrain, CEO of IBA. This financing will enable the startup, incubated at iPEPS, the Incubator and Business Nursery of Paris-Salp\u00eatri\u00e8re, to expand into European and North American markets.<\/p>\n\n\n\n\n\n\n\n

\"\"<\/figure>\n\n\n\n

With this funding round, the startup will have raised a total of 12 million Euros, including a 4.7 million Euro round in 2021 and 2.5 million Euros in grants from the European Commission’s EIC Accelerator.<\/strong> The startup has also been selected to receive up to 9 million Euros in capital through the EIC Fund. neuroClues\u00ae is also the winner of the HealthTech For Care innovation Prize, awarded in October 2023 in Paris by Bernard Hinault.<\/p>\n\n\n\n

The only eye-tracking solution developed for primary care medicine<\/h2>\n\n\n\n

After three years of development, neuroClues\u00ae has implemented a new technology based on eye movement analysis, or eye-tracking, to diagnose neurodegenerative diseases<\/strong> earlier than currently possible.
This solution includes an innovative headset controlled from an intuitive interface. Placed in front of the patient’s eyes, the headset can record up to 800 infrared images per eye per second while the patient follows a moving point on a screen. Compact and portable, this analysis tool meets the needs of both daily practice and research.<\/p>\n\n\n\n

As simple as the “follow my finger” test, it analyzes eye movements within minutes to identify precise, objective, quantifiable, and non-invasive biomarkers.<\/strong><\/p>\n\n\n\n

These biomarkers help determine neurological disorders (Parkinson’s disease, Alzheimer’s disease, multiple sclerosis, etc.) several years before the onset of clinical symptoms such as memory loss or tremors.<\/strong><\/p>\n\n\n\n

\"\"<\/figure>\n\n\n\n

A major challenge when considering that neurodegenerative diseases, which are constantly increasing, are often misdiagnosed and diagnosed late. Indeed, evaluation is usually given when the stage of neurological degradation is already advanced. For Parkinson’s disease alone, one in four patients is misdiagnosed and waits an average of 13 months before receiving a diagnosis. When diagnosed, they are left with only 35% of dopamine-producing neurons.<\/strong> These issues will only worsen as the number of affected patients doubles over the next decade, reaching 13 million by 2040. The global market addressed by neuroClues\u00ae is currently estimated at 2.5 million doctors using eye movement observation to assess the neurological status of their patients during clinical consultations.<\/strong><\/p>\n\n\n\n

Parkinson’s disease: neuroClues\u00ae is at the heart of the Iceberg study by the Brain Institute<\/h2>\n\n\n\n

Since the fall of 2023, a subset of patients in the Iceberg scientific cohort, led by Professors Marie Vidailhet and St\u00e9phane Leh\u00e9ricy of the Brain Institute at La Salp\u00eatri\u00e8re Hospital in Paris, has been benefiting from a prototype of neuroClues\u00ae technology. This opens new hopes for Parkinson’s disease research, both in terms of diagnosis and long-term patient monitoring<\/strong>. neuroClues\u00ae indeed helps researchers quantify disease biomarkers much more simply and extremely accurately.<\/strong><\/p>\n\n\n\n

\"Pr<\/figure>\n\n\n\n
\n

Indeed, subtle alterations in eye movement parameters can precede the onset of gait and balance disturbances, detecting early dysfunction in brain circuits in Parkinson’s disease before symptoms appear. This detection will enable earlier implementation of care by enhancing patient capabilities (compensation). This may involve, for example, physical and sports training, monitoring, and management of risk factors: the patient becomes their own therapist!<\/em><\/p>\nPr Marie Vidailhet, Neurology Professor at the Piti\u00e9-Salp\u00eatri\u00e8re and head of the “Mov It” team at the ICM<\/cite><\/blockquote>\n\n\n\n

\n
Parkinson’s disease: what is the situation?<\/a><\/blockquote>